AKAO Achaogen, Inc.

21.64
-0.44  -2%
Previous Close 22.08
Open 22.02
Price To book 10.06
Market Cap 775.86M
Shares 35,853,000
Volume 781,428
Short Ratio 3.96
Av. Daily Volume 886,256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2Q 2017.
C-Scape
Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - EPIC trial
Complicated urinary tract infections (cUTI)
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)

Latest News

  1. Achaogen, Inc. breached its 50 day moving average in a Bearish Manner : AKAO-US : May 26, 2017
  2. Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2017 Annual Meeting
  3. Achaogen Announces Pricing of Public Offering of Common Stock
  4. Achaogen's Plazomicin Gets Breakthrough Therapy Designation
  5. Plazomicin Granted FDA Breakthrough Therapy Designation
  6. Achaogen Announces Proposed Public Offering of Common Stock
  7. Top 4 Pharmaceutical Stocks for 2017
  8. Four Stocks Moving On Both News And The Charts
  9. Achaogen reports 1Q loss
  10. Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update
  11. Investor Network: Achaogen, Inc. to Host Earnings Call
  12. Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria
  13. Achaogen to Host Conference Call and Webcast of First Quarter 2017 Financial Results on May 8, 2017
  14. Achaogen, Inc. – Value Analysis (NASDAQ:AKAO) : April 28, 2017
  15. Achaogen, Inc. breached its 50 day moving average in a Bullish Manner : AKAO-US : April 27, 2017
  16. Achaogen Unveils Data Highlighting the Effectiveness of Plazomicin Against MDR Gram-Negative Bacteria at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  17. Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  18. Achaogen, Inc. breached its 50 day moving average in a Bearish Manner : AKAO-US : April 11, 2017
  19. Achaogen to Present at Needham & Company’s 16th Annual Healthcare Conference